4 reports

  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • MAR 02, 2016: CHI-MED INITIATES SULFATINIB PHASE II CLINICAL TRIAL IN THYROID CANCER
  • JAN 16, 2017: CHI-MED INITIATES A PHASE II STUDY OF SULFATINIB IN SECOND-LINE BILIARY TRACT CANCER IN CHINA

Summary Hutchison MediPharma Ltd (HMPL), a subsidiary of Hutchison China MediTech Ltd is a biopharmaceutical company that discovers, develops and commercializes therapeutics in oncology and autoimmune diseases. The company’s products comprise savolitinib, fruquintinib, sulfatinib, hmpl-523, epitinib, theliatinib, HMPL-453,...

  • Cancer
  • Clinical Research
  • Healthcare
  • Pharmaceutical
  • Hutchison MediPharma Limited
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development
  • Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • HUTCHISON MEDIPHARMA LTD - PIPELINE BY INDICATION, 2016
  • HMPL-518 - DRUG PROFILE

Hutchison MediPharma Ltd - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Hutchison MediPharma Ltd - Product Pipeline Review - 2016’, provides an overview of the Hutchison MediPharma Ltd’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics...

  • Cancer
  • World
  • Company Operations
  • Product Initiative
  • Hutchison MediPharma Limited